These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21476971)

  • 21. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human hepatic cytochrome P450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon.
    Ellison CA; Tian Y; Knaak JB; Kostyniak PJ; Olson JR
    Drug Metab Dispos; 2012 Jan; 40(1):1-5. PubMed ID: 21969518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.
    Rehmel JL; Eckstein JA; Farid NA; Heim JB; Kasper SC; Kurihara A; Wrighton SA; Ring BJ
    Drug Metab Dispos; 2006 Apr; 34(4):600-7. PubMed ID: 16415119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
    Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
    Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of a higher throughput approach to derive apparent Michaelis-Menten constants of isoform-selective p450-mediated biotransformation reactions in human hepatocytes.
    Li AP; Schlicht KE
    Drug Metab Lett; 2014; 8(1):2-11. PubMed ID: 24910237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.
    Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T
    Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
    Lee KS; Kim SK
    J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
    Lewis DF
    Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.
    Koyama E; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1996 Jul; 278(1):21-30. PubMed ID: 8764331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic characterization of the major human small intestinal cytochrome p450s.
    Obach RS; Zhang QY; Dunbar D; Kaminsky LS
    Drug Metab Dispos; 2001 Mar; 29(3):347-52. PubMed ID: 11181505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
    Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
    Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol.
    Iwaki M; Niwa T; Bandoh S; Itoh M; Hirose H; Kawase A; Komura H
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):425-432. PubMed ID: 27836712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
    Houston JB; Kenworthy KE
    Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.
    Kassahun K; McIntosh IS; Shou M; Walsh DJ; Rodeheffer C; Slaughter DE; Geer LA; Halpin RA; Agrawal N; Rodrigues AD
    Drug Metab Dispos; 2001 Jun; 29(6):813-20. PubMed ID: 11353749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach.
    Rodrigues AD
    Drug Metab Lett; 2007 Jan; 1(1):31-5. PubMed ID: 19356015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of human liver microsomal CYP by nateglinide.
    Takanohashi T; Kubo S; Nakayama A; Mihara R; Hayashi M
    J Pharm Pharmacol; 2010 May; 62(5):592-7. PubMed ID: 20609060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.